A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308).
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
AMGEN SA
Cita
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308). (20230298). AMGEN SA. 2024IP:ÓSCAR JOSÉ JUAN VIDAL.
Portal de investigación